Northland Securities Weighs in on TLSI FY2025 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Stock analysts at Northland Securities issued their FY2025 EPS estimates for shares of TriSalus Life Sciences in a report issued on Monday, March 2nd. Northland Securities analyst C. Byrnes forecasts that the company will post earnings per share of ($0.85) for the year. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

A number of other analysts have also commented on the company. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Finally, Canaccord Genuity Group boosted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, TriSalus Life Sciences has an average rating of “Hold” and a consensus price target of $12.00.

TriSalus Life Sciences Trading Up 1.2%

Shares of NASDAQ TLSI opened at $5.00 on Wednesday. The company has a market cap of $250.30 million, a price-to-earnings ratio of -2.48 and a beta of 0.42. The stock has a 50-day moving average price of $5.46 and a two-hundred day moving average price of $5.36. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences in the first quarter valued at approximately $187,000. Geode Capital Management LLC raised its holdings in TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at $29,000. JPMorgan Chase & Co. grew its holdings in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. Finally, Connective Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after acquiring an additional 3,717 shares during the last quarter. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.